On May 8th, President Clinton announced a major victory in ensuring people living with HIV/AIDS in poor and middle income countries can access the highest quality treatment available. CHAI, in partnership with UNITAID has reached an agreement with with leading pharmaceutical manufacturers Cipla and Matrix, resulting in major price reductions for 16 medicines critical to fighting HIV/AIDS. Included in this agreement are reduced prices for both second-line medicines and a “gold-standard” one-pill, once-daily first-line medicine.

Poor countries around the globe struggle to afford the cost of high-quality treatment for patients in need. In middle income countries, in Latin America and Asia treatment is much more expensive than in low income countries. But people living with HIV/AIDS in those countries are no less in need. It is CHAI’s objective to ensure patients have access regardless of where they live. Today’s agreement is another important step towards making equal access to treatment a reality.

This agreement is one in a series of price reductions CHAI has helped champion since 2002. Reducing the price of medicines is a key component to reaching CHAI’s goal of making high-quality treatment equally available to people in need across the developing world. In order to curb this pandemic, the best treatment and technology science has to offer should be available to everyone, and all drugs needed to fight HIV/AIDS must be available to the two million people now on treatment in developing countries — and the five million more still waiting for access around the world.

Download Clinton Foundation HIV/AIDS Initiative Overview 
Download the latest ARV Price List